BioWorld

Aug. 18, 2008

View Archived Issues

Cytos Signs $139M Deal with Pfizer for Immunodrug Vaccines

As three of its own Immunodrug vaccine candidates advance through clinical trials, Cytos Biotechnology AG signed a CHF150 (US$139 million) technology deal with Pfizer Inc.'s vaccine unit. (BioWorld Today) Read More

Aiming for Profitability, Nanogen Signs Merger Deal with Elitech

Read More

Oxford BioMedica Rejects 'Surprise' GeneThera Offer

Read More

Prestwick's Xenazine Gains First U.S. OK for Huntington's

Read More

Metronomic Dosing Successful in NCI Prostate Cancer Vaccine Trial

Read More

Clinic Roundup

Read More

Other News To Note

Read More